We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021): Virtual. 19-21 September 2021.
- Abstract
Overall, 18 patients received a cumulative dose <2700 mg and 34 patients received 2700-5400 mg, while 14 patients received a cumulative dose of >5400 mg. The safety and efficacy were analyzed separately in three subgroups of patients receiving a cumulative dose of less than <2700 mg, >=2700-5400mg or >5400 mg B Results: b Of the 74 MKD patients who started the CLUSTER study, 66 entered Epoch 4 and 65 completed it. At the start of Epoch 4, 19 patients (29%) were receiving the lowest dose regimen (150mg q8) and in 12 (18%) this dose was sufficient to control the disease throughout epoch 4.
- Subjects
PEDIATRIC rheumatology; MEVALONATE kinase
- Publication
Pediatric Rheumatology, 2021, Vol 19, Issue 1, p1
- ISSN
1546-0096
- Publication type
Article
- DOI
10.1186/s12969-021-00632-z